CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response
Blood Adv
.
2023 Oct 10;7(19):5937-5940.
doi: 10.1182/bloodadvances.2023010127.
Authors
Othman S Akhtar
1
,
Biwei Cao
2
,
Xuefeng Wang
2
,
Pallawi Torka
3
,
Mohammed Al-Jumayli
4
,
Frederick L Locke
1
,
Ciara L Freeman
1
Affiliations
1
Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.
2
Department of Bioinformatics and Biostatistics, Moffitt Cancer Center, Tampa, FL.
3
Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
4
Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL.
PMID:
37236167
PMCID:
PMC10562759
DOI:
10.1182/bloodadvances.2023010127
No abstract available
MeSH terms
Aged
Antigens, CD19
Humans
Immunotherapy, Adoptive*
Lymphoma, Large B-Cell, Diffuse* / therapy
Transplantation, Autologous
Substances
Antigens, CD19
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States